1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Revenio Group Oyj
  6. News
  7. Summary
    REG1V   FI0009010912

REVENIO GROUP OYJ

(REG1V)
  Report
Real-time Estimate Cboe Europe  -  06:48 2022-07-07 am EDT
43.20 EUR   -0.41%
05/23REVENIO GROUP CORPORATION : Managers' Transactions – Ari Isomäki
AQ
05/20REVENIO GROUP CORPORATION : Managers' Transactions – Heli Huopaniemi
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Arne Boye Nielsen
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Revenio Group Corporation: Managers' Transactions – Arne Boye Nielsen

05/11/2022 | 08:01am EDT

Revenio Group Corporation, Managers’ transactions, May 11, 2022 at 3.00 p.m. (EEST)

Revenio Group Corporation: Managers' Transactions – Arne Boye Nielsen

____________________________________________

Person subject to the notification requirement

Name: Arne Boye Nielsen
Position: Member of the Board/Deputy member
Issuer: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04
Notification type: INITIAL NOTIFICATION
Reference number: 14611/7/6
____________________________________________

Transaction date: 2022-05-11
Venue not applicable
Instrument type: SHARE
ISIN: FI0009010912
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details
(1): Volume: 557 Unit price: 0 N/A
Aggregated transactions
(1): Volume: 557 Volume weighted average price: 0 N/A

For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
www.revenio.fi

Distribution
Nasdaq Helsinki Ltd
Main media
www.revenio.fi

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare software solutions provide eye care professionals with new innovative digital clinical tools that drive greater efficiency and enhance the quality of care.

In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

© Modular Finance, source Nordic Press Releases

All news about REVENIO GROUP OYJ
05/23REVENIO GROUP CORPORATION : Managers' Transactions – Ari Isomäki
AQ
05/20REVENIO GROUP CORPORATION : Managers' Transactions – Heli Huopaniemi
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Arne Boye Nielsen
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Ann-Christine Sundell
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Bill Östman
AQ
05/11REVENIO GROUP CORPORATION : Transfer of the Company's own shares
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Riad Sherif
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Pekka Tammela
AQ
04/28TRANSCRIPT : Revenio Group Oyj, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Revenio Group Corporation's Vice Chairman has been elected
AQ
More news
Financials
Sales 2022 93,7 M 95,4 M 95,4 M
Net income 2022 22,1 M 22,5 M 22,5 M
Net cash 2022 10,7 M 10,9 M 10,9 M
P/E ratio 2022 51,8x
Yield 2022 0,93%
Capitalization 1 152 M 1 173 M 1 173 M
EV / Sales 2022 12,2x
EV / Sales 2023 10,1x
Nbr of Employees 184
Free-Float 80,0%
Chart REVENIO GROUP OYJ
Duration : Period :
Revenio Group Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVENIO GROUP OYJ
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 43,38 €
Average target price 49,13 €
Spread / Average Target 13,2%
EPS Revisions
Managers and Directors
Jouni Erik Toijala President & Chief Executive Officer
Robin Allan Pulkkinen Chief Financial Officer
Arne Boye Nielsen Chairman
Mika Salkola Director-Research & Development
Ari Isomäki Operations Director
Sector and Competitors